Long-Term Management with Adipose Tissue-Derived Mesenchymal Stem Cells and Conventional Treatment in a Dog with Hepatocutaneous Syndrome

A 10-year-old Maltese dog diagnosed with hepatocutaneous syndrome (HS) was treated with a combination of conventional therapies and 46 infusions of allogenic adipose tissue-derived mesenchymal stem cells over 30 months. The dog initially showed significant improvement, including hair regrowth and reduction of skin lesions. However, the dog eventually succumbed to severe azotemia and died despite intensive care, with necropsy revealing severe liver fibrosis and superficial necrolytic dermatitis. The dog survived 32 months post-diagnosis, suggesting that a combination of amino acid and stem cell therapy might be beneficial for managing HS.